Tirzepatide
Also known as: LY3298176, Mounjaro, Zepbound
5 notable studies · 6 references
TLDR
Tirzepatide is an FDA-approved once-weekly dual GIP and GLP-1 receptor agonist with extensive human evidence for type 2 diabetes and obesity, including substantial sustained weight reduction, reduced progression from prediabetes to diabetes during long-term treatment, and an FDA-approved indication for obesity-associated moderate-to-severe obstructive sleep apnea. PubMed
Research Supports
- FDA-approved for type 2 diabetes glycemic control and chronic weight management
- Studied for obesity-related obstructive sleep apnea
- Investigated for cardiovascular outcomes versus dulaglutide
- Examined for diabetes-prevention effects in adults with prediabetes
- Compared directly against semaglutide for weight and glycemic outcomes
Observations Reported in Research
- SURMOUNT-1: -20.9% average weight change at 72 weeks with 15 mg vs -3.1% placebo (2022)
- Outperformed semaglutide 1 mg for HbA1c and weight reduction in SURPASS-2 (2021)
- Reduced progression to type 2 diabetes to 1.3% vs 13.3% with placebo over 176 weeks in people with prediabetes (2025)
- SURMOUNT-5: -20.2% weight change vs -13.7% with semaglutide (2025)
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Long-acting single-peptide dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R)
Tirzepatide is a once-weekly peptide that activates both the GIP and GLP-1 receptors. It was originally developed for type 2 diabetes and subsequently became one of the most extensively studied pharmacological treatments for obesity. In the United States, tirzepatide is FDA-approved as: Mounjaro — for improving glycemic control in type 2 diabetes. Zepbound — for chronic weight management in qualifying adults and, since December 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity. Zepbound was the first medication FDA approved specifically for OSA in this population. U.S. Food and Drug Administration Its obesity evidence is substantial. In SURMOUNT-1, average weight reduction at 72 weeks reached 20.9% with 15 mg, compared with 3.1% with placebo. PubMed A three-year extension in participants with obesity and prediabetes subsequently showed sustained weight reduction and a markedly lower rate of progression to type 2 diabetes. PubMed
What Is Tirzepatide?
Tirzepatide is an engineered 39-amino-acid peptide designed to activate two incretin hormone receptors within a single molecule. Those receptors are: GIPR — glucose-dependent insulinotropic polypeptide receptor GLP-1R — glucagon-like peptide-1 receptor The molecule includes a fatty-acid modification that promotes albumin binding and prolongs exposure sufficiently for once-weekly administration. Early pharmacological characterization showed activity at both human GIP and GLP-1 receptors. PubMed This makes tirzepatide fundamentally different from semaglutide, which targets GLP-1R without directly activating GIPR. It also distinguishes tirzepatide from retatrutide: Tirzepatide → GIP + GLP-1 Retatrutide → GIP + GLP-1 + glucagon
What Are Researchers Studying?
Type 2 diabetes and glycemic control
Type 2 diabetes was tirzepatide's original major clinical-development program. The SURPASS Phase 3 program demonstrated substantial reductions in HbA1c across diverse populations and comparator treatments. In SURPASS-2, tirzepatide was compared directly with semaglutide 1 mg in 1,879 adults with type 2 diabetes. All three tirzepatide doses produced greater average HbA1c reductions than semaglutide 1 mg at 40 weeks. Tirzepatide also produced greater reductions in body weight. PubMed
Obesity and body-weight regulation
SURMOUNT-1 randomized 2,539 adults with obesity or overweight without diabetes. At 72 weeks, average body-weight changes were: 5 mg: −15.0% 10 mg: −19.5% 15 mg: −20.9% Placebo: −3.1% More than half of participants receiving 10 or 15 mg achieved at least 20% weight reduction. PubMed This established tirzepatide as a major obesity pharmacotherapy.
Obesity versus semaglutide
The 2025 SURMOUNT-5 trial provided an especially useful direct comparison. Researchers randomized 751 adults with obesity without diabetes to maximum tolerated doses of tirzepatide or semaglutide. At 72 weeks, average weight change was: Tirzepatide: −20.2% Semaglutide: −13.7% Average waist-circumference reductions were 18.4 cm and 13.0 cm, respectively. Tirzepatide was superior for both primary weight reduction and waist-circumference outcomes. PubMed This finding applies to the specific doses, populations, and treatment conditions tested; it should not be simplified into “tirzepatide is always better than semaglutide.”
Prediabetes and progression to type 2 diabetes
The three-year SURMOUNT-1 extension provides unusually long controlled evidence for a modern obesity medication. Researchers followed 1,032 participants with obesity and prediabetes for 176 weeks of treatment. At week 176, average weight changes were: 5 mg: −12.3% 10 mg: −18.7% 15 mg: −19.7% Placebo: −1.3% Type 2 diabetes developed in 1.3% of tirzepatide-treated participants versus 13.3% receiving placebo during the treatment period. After an additional 17 weeks off treatment, the corresponding figures were 2.4% and 13.7%. PubMed This is strong evidence that tirzepatide can delay progression to diabetes in this studied population during prolonged treatment.
Obstructive sleep apnea
Tirzepatide has been studied specifically in adults with obesity and moderate-to-severe obstructive sleep apnea. The evidence ultimately resulted in FDA approval of Zepbound for this indication in December 2024. The FDA concluded that improvements were demonstrated using the apnea-hypopnea index, which measures the frequency of apnea and hypopnea events during sleep. U.S. Food and Drug Administration This is an important example of obesity pharmacotherapy being studied against a specific obesity-associated disease rather than body weight alone.
Cardiovascular outcomes
Cardiovascular outcomes have become an increasingly important part of tirzepatide research. The dedicated SURPASS-CVOT program compared tirzepatide with dulaglutide in people with type 2 diabetes and established cardiovascular disease. By 2026, the cardiovascular-outcomes literature supported noninferiority of tirzepatide for major adverse cardiovascular events. PubMed This evidence should be kept separate from changes in cardiovascular risk factors such as body weight, blood pressure, lipids, and predicted risk scores. Improving those markers does not automatically prove prevention of heart attacks, strokes, or cardiovascular death.
How Does It Work?
Tirzepatide activates two receptors. GIP receptor GIP is an endogenous incretin hormone released from the intestine after nutrient intake. GIPR activation can influence: • Glucose-dependent insulin secretion • Pancreatic beta-cell function • Adipose-tissue biology • Nutrient handling • Central nervous system pathways involved in energy balance GLP-1 receptor GLP-1R activation can: • Increase glucose-dependent insulin secretion • Reduce inappropriate glucagon secretion during hyperglycemia • Reduce appetite and energy intake • Affect gastric emptying • Improve glycemic control Tirzepatide integrates both activities into a single molecule. Importantly, scientists are still working out exactly how much GIPR activation contributes to tirzepatide's clinical effects. The importance of the GIP component cannot simply be inferred from the fact that tirzepatide outperforms some GLP-1-only treatments. PubMed Human biomarker analyses have shown improvements in both beta-cell function and insulin-sensitivity measures during tirzepatide treatment. PubMed
What Does the Research Show?
Human research
The human evidence for tirzepatide is extensive. It includes: • Phase 1 pharmacology studies • Large Phase 2 trials • Multiple Phase 3 diabetes trials • Multiple Phase 3 obesity trials • Active comparisons with insulin • Active comparisons with GLP-1 receptor agonists • Three-year controlled obesity/prediabetes follow-up • Obstructive sleep apnea trials • Cardiovascular-outcomes research This makes tirzepatide fundamentally different from many compounds in Aminodex. The central research question is no longer: “Does tirzepatide work in humans?” That is well established for its approved indications. The more interesting current questions concern: • Long-term outcomes • Disease prevention • Treatment durability • Body composition • Cardiovascular outcomes • Effects after discontinuation • Which receptor contributes what • How tirzepatide compares with next-generation multi-agonists
Animal research
Preclinical studies were critical during tirzepatide's development. Researchers investigated: • GIPR and GLP-1R pharmacology • Insulin secretion • Glucose regulation • Food intake • Body weight • Energy expenditure • Adipose metabolism Animal experiments helped demonstrate that combining GIPR and GLP-1R agonism within one molecule could produce metabolic effects beyond those expected from either pathway alone. However, tirzepatide now has enough direct human evidence that animal results should generally serve a mechanistic, rather than efficacy-defining, role on Aminodex.
In-vitro research
Tirzepatide has been extensively characterized in receptor-expression systems. The original discovery program demonstrated activity at both GIPR and GLP-1R and helped establish the receptor balance selected for clinical development. PubMed Cellular research has subsequently examined: • Receptor binding • cAMP signaling • Receptor internalization • Beta-arrestin recruitment • Biased agonism • Differences from native GLP-1 and GIP This molecular pharmacology remains an active research area because receptor signaling is more complicated than simply labeling tirzepatide a “50/50” dual agonist.
Notable Studies
LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus: From Discovery to Clinical Proof of Concept
humanResearchers characterized LY3298176, later named tirzepatide, as a single peptide capable of activating both GIP and GLP-1 receptors. The program combined receptor experiments, animal research, and early human testing and established the pharmacological rationale for dual GIP/GLP-1 agonism. PubMed
Limitations: Early proof-of-concept research could not establish long-term efficacy, safety, cardiovascular outcomes, or durability.
View publication →Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
humanResearchers compared tirzepatide 5, 10, and 15 mg with semaglutide 1 mg in 1,879 adults with type 2 diabetes. Tirzepatide was noninferior and superior to semaglutide for average HbA1c reduction. Body-weight reduction was also greater with each tirzepatide dose, with estimated between-treatment differences of approximately 1.9, 3.6, and 5.5 kg for the three tirzepatide doses. PubMed
Limitations: The comparator was semaglutide 1 mg, the diabetes dose used in the trial—not semaglutide 2.4 mg used for obesity treatment. The study lasted 40 weeks and was not a cardiovascular-outcomes trial.
View publication →Tirzepatide Once Weekly for the Treatment of Obesity
humanResearchers randomized 2,539 adults with obesity or overweight without diabetes to tirzepatide 5, 10, or 15 mg or placebo for 72 weeks. Average body-weight changes were: 5 mg: −15.0% 10 mg: −19.5% 15 mg: −20.9% Placebo: −3.1% At least 20% weight reduction occurred in 50% of participants receiving 10 mg and 57% receiving 15 mg, versus 3% with placebo. PubMed
Limitations: Participants with diabetes were excluded. The initial study period could not establish multi-year durability, cardiovascular outcomes, or what occurs after long-term discontinuation.
View publication →Tirzepatide for Obesity Treatment and Diabetes Prevention
humanResearchers followed participants with obesity and prediabetes for 176 weeks of treatment, followed by 17 weeks off treatment. At 176 weeks, weight reduction remained substantial, reaching an average 19.7% with tirzepatide 15 mg. During treatment, type 2 diabetes developed in 1.3% of tirzepatide-treated participants versus 13.3% receiving placebo, corresponding to a hazard ratio of 0.07. PubMed
Limitations: The diabetes-prevention analysis involved the subgroup with prediabetes at baseline. The trial demonstrates markedly reduced progression during treatment but does not prove permanent prevention after medication discontinuation.
View publication →Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
humanResearchers randomized 751 adults with obesity without diabetes to maximum tolerated doses of tirzepatide or semaglutide for 72 weeks. Average weight reduction was: Tirzepatide: −20.2% Semaglutide: −13.7% Average waist circumference decreased 18.4 cm with tirzepatide versus 13.0 cm with semaglutide. Tirzepatide was superior for the trial's weight and waist-circumference outcomes. PubMed
Limitations: The trial was open-label. It evaluated maximum tolerated doses under a specific clinical-trial protocol and did not establish superiority for every outcome or every individual patient.
View publication →What We Still Don't Know
Despite its unusually large evidence base, important questions remain: • Multi-decade safety • Weight and metabolic trajectories after many years of treatment • Long-term outcomes after discontinuation • Optimal strategies for maintaining weight reduction • Precise contribution of GIPR activation to clinical efficacy • Long-term changes in lean versus fat mass • Effects across different phenotypes of obesity • How much diabetes prevention persists after treatment stops • Whether next-generation triple agonists provide clinically meaningful advantages • How tirzepatide compares long-term with combination amylin/incretin therapies • Which patients respond particularly strongly or poorly • Long-term cardiovascular, renal, and other disease-specific outcomes across different populations The three-year SURMOUNT-1 data already answer more long-term questions than we have for many newer metabolic peptides, but they also show why on-treatment benefit and permanent disease modification aren't the same thing. PubMed
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the Tirzepatide research with you.
Get the Aminodex Tirzepatide Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus: From Discovery to Clinical Proof of Concept. Molecular Metabolism. 2018;18:3–14.
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205–216.
- Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. New England Journal of Medicine. 2025;392:958–971.
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. 2025;393:26–36.
- U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea. December 20, 2024.
Supplier Listings
Disclosure: The owner of Aminodex operates the supplier(s) marked below. These listings are promotion for businesses we own, not independent recommendations. Read our disclosures.